Steven Van Schandevyl

Steven Van Schandevyl

Auto-generated profile, based on publicly available information

Steven Van Schandevyl

Nuclear Medicine, Ghent University Hospital, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2018 in Acta Clinica Belgica
Verified
Journal Article
Closed access
SSSteven Van Schandevyl
Steven Van Schandevyl
TKTessa C. Kerre
Tessa C. Kerre
Objectives: To summarize important findings from research on chimeric antigen receptor (CAR) T-cell immunotherapy in cancer. We discuss CAR design, cell products, toxicity management, heterogenous solid tumors and allogeneic transfer. Methods: A review of literature was conducted. The available literature was selected on original research, state-of-the art design, relevance to the objective and journal impact factor. Results: First-generation CARs provide patient T cells with tumor-specific antigen recognition. Second- and third-generation CARs incorporate costimulatory domains for enhanced T-cell persistence and antitumor activity. Fourth-generation CAR T cells (TRUCKs) include a cytokine production cassette, and hold promise in the treatment of heterogenous solid tumors. Transduced cell phenotype and subset composition are important factors. Suicide genes and safety switches are designed to decrease potential toxicity. Multi-specific CAR T cells can address heterogenous tumors. Allogeneic, off-the-shelf CAR T cells might reduce the production delay. Conclusion: CAR T cells have revolutionized the immunotherapeutic treatment of cancer: exciting results in refractory and relapsed B-cell malignancies have been published. Neurologic complications, solid tumor management and allogeneic constructs require further research. In conclusion, further design adjustments will enable CAR T cells to decisively reshape the field of cancer immunotherapy.

19 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JBJacqueline Bijnens
Jacqueline Bijnens
ABAnnick Van den Bruel
Annick Van den Bruel
Vincent Vander PoortenVincent Vander Poorten
Vincent Vander Poorten
IGIngeborg Goethals
Ingeborg Goethals
SSSteven Van Schandevyl
Steven Van Schandevyl
FGFrank De Geeter
Frank De Geeter
The objective of this study was to retrospectively evaluate preoperative imaging modalities for localization of parathyroid adenomas with a view to enable minimally invasive parathyroidectomy and in particular, to consider the contribution of 18F-fluorocholine-PET/CT. 104 patients with primary hyperparathyroidism, who underwent parathyroid surgery in a single centre during a 6-year period were included. Of these, 103 underwent ultrasound, 97 99mTc-Pertechnetate/SestaMIBI-SPECT, 20 MRI and 30 18F-fluorocholine-PET/CT. Based on surgical findings, sensitivities and specificities for correct lateralisation in orthotopic locations were: for ultrasound 0.75 (0.65–0.83) and 0.89 (0.81–0.94), for 99mTc-MIBI-SPECT 0.57 (0.46–0.67) and 0.97 (0.91–0.99), for MRI 0.60 (0.36–0.81) and 0.83 (0.59–0.96) and for 18F-fluorocholine-PET/CT 0.90 (0.73–0.98) and 0.90 (0.73–0.98). Correctly lateralized adenomas were significantly larger than those not found with ultrasound (p = 0.03) and SPECT (p = 0.002). Pre-operative PTH-levels were higher in single adenomas detected by scintigraphy than in those not (p = 0.02). 64 patients could be treated with a minimally invasive procedure. Cure after parathyroidectomy was obtained in 94% of patients. 18F-Fluorocholine-PET/CT could be shown to be a highly accurate modality to localize parathyroid adenomas preoperatively, obviating the need for total exploration in the majority of patients in whom ultrasound and scintigraphic results are discordant or both negative.

29 November 2018 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
SSSteven Van Schandevyl
Steven Van Schandevyl
LCLiselotte Coorevits
Liselotte Coorevits
JBJerina Boelens
Jerina Boelens
ATAns Traen
Ans Traen
LBLuc Bingé
Luc Bingé
EPElizaveta Padalko
Elizaveta Padalko

1 April 2020 in Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
SSSteven Van Schandevyl
Steven Van Schandevyl
RWRobbe Waterschoot
Robbe Waterschoot
NVNicolas De Vos
Nicolas De Vos
DDDaniel Devos
Daniel Devos
IGIngeborg Goethals
Ingeborg Goethals